Symbols / SNOA $2.37 -2.47% Sonoma Pharmaceuticals, Inc.
SNOA Chart
About
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 4.10M |
| Enterprise Value | 2.20M | Income | -3.37M | Sales | 17.72M |
| Book/sh | 1.98 | Cash/sh | 1.48 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | — | Forward P/E | -4.23 | PEG | — |
| P/S | 0.23 | P/B | 1.20 | P/C | — |
| EV/EBITDA | -0.83 | EV/Sales | 0.12 | Quick Ratio | 1.21 |
| Current Ratio | 2.88 | Debt/Eq | 19.09 | LT Debt/Eq | — |
| EPS (ttm) | -1.95 | EPS next Y | -0.56 | EPS Growth | — |
| Revenue Growth | 22.00% | Earnings | 2026-02-10 16:00 | ROA | -12.67% |
| ROE | -81.18% | ROIC | — | Gross Margin | 38.16% |
| Oper. Margin | -15.59% | Profit Margin | -19.02% | Shs Outstand | 1.73M |
| Shs Float | 1.71M | Short Float | 0.99% | Short Ratio | 1.23 |
| Short Interest | — | 52W High | 6.92 | 52W Low | 1.75 |
| Beta | 1.76 | Avg Volume | 22.05K | Volume | 9.46K |
| Target Price | $12.00 | Recom | None | Prev Close | $2.43 |
| Price | $2.37 | Change | -2.47% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-09-05 | init | Ladenburg Thalmann | — → Buy | $3 |
| 2018-03-06 | down | Maxim Group | Buy → Hold | — |
| 2017-12-28 | init | Benchmark | — → Speculative Buy | $10 |
| 2017-11-10 | main | Maxim Group | — → Buy | $11 |
- Burn relief gel for minor burns heads to CVS and Walmart nationwide - Stock Titan ue, 24 Mar 2026 07
- Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock - Yahoo Finance ue, 19 Aug 2025 07
- Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Could Be Riskier Than It Looks - simplywall.st Wed, 14 Jan 2026 08
- New Aquanil AD skin line uses hypochlorous acid for sensitive, irritated skin - Stock Titan Wed, 18 Mar 2026 07
- Should I buy Sonoma Pharmaceuticals (SNOA) - Zacks Investment Research Mon, 14 Jul 2025 07
- Will Sonoma Pharma’s New Product Boost Its Stock? - StocksToTrade hu, 14 Aug 2025 07
- symbol__ Stock Quote Price and Forecast - CNN Fri, 05 Jan 2024 18
- SNOA Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI ue, 13 May 2025 12
- Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 20 - GuruFocus ue, 17 Jun 2025 07
- Sonoma Pharmaceuticals Soars 95% After Walmart, Amazon Retail Debut - Yahoo Finance hu, 14 Aug 2025 07
- Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results - The Globe and Mail ue, 04 Nov 2025 08
- Trending Stocks Today | Sonoma Pharmaceuticals Shoots up 41.8% Post-Market - Moomoo Wed, 13 Aug 2025 07
- Sonoma Pharmaceuticals Stock Price Forecast. Should You Buy SNOA? - StockInvest.us hu, 10 Dec 2020 04
- SNOA Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 01
- Sonoma Pharmaceuticals, Inc. (SNOA) stock price, news, quote and history - Yahoo Finance UK Mon, 22 May 2017 01
Insider Transactions
Financials
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
14.29
+12.19%
|
12.73
-4.05%
|
13.27
+5.10%
|
12.63
|
| Operating Revenue |
|
14.29
+12.19%
|
12.73
-4.05%
|
13.27
+5.10%
|
12.63
|
| Cost Of Revenue |
|
8.82
+10.43%
|
7.99
-9.15%
|
8.79
+1.85%
|
8.63
|
| Reconciled Cost Of Revenue |
|
8.82
+10.43%
|
7.99
-9.15%
|
8.79
+1.85%
|
8.63
|
| Gross Profit |
|
5.46
+15.17%
|
4.75
+5.99%
|
4.48
+12.12%
|
3.99
|
| Operating Expense |
|
9.18
-2.87%
|
9.45
+4.41%
|
9.05
-8.43%
|
9.88
|
| Research And Development |
|
1.81
-3.05%
|
1.87
+803.86%
|
0.21
+65.60%
|
0.12
|
| Selling General And Administration |
|
7.36
-2.83%
|
7.58
-14.31%
|
8.84
-9.38%
|
9.76
|
| Total Expenses |
|
18.00
+3.22%
|
17.44
-2.28%
|
17.84
-3.63%
|
18.52
|
| Operating Income |
|
-3.71
+21.08%
|
-4.70
-2.87%
|
-4.57
+22.37%
|
-5.89
|
| Total Operating Income As Reported |
|
-3.71
+21.08%
|
-4.70
-2.87%
|
-4.57
+22.37%
|
-5.89
|
| EBITDA |
|
-3.57
+21.06%
|
-4.53
-1.80%
|
-4.45
+22.03%
|
-5.70
|
| Normalized EBITDA |
|
-3.57
+21.06%
|
-4.53
-1.80%
|
-4.45
+32.39%
|
-6.57
|
| Reconciled Depreciation |
|
0.14
-21.59%
|
0.18
+40.80%
|
0.12
-32.80%
|
0.19
|
| EBIT |
|
-3.71
+21.08%
|
-4.70
-2.87%
|
-4.57
+22.37%
|
-5.89
|
| Total Unusual Items |
|
—
|
—
|
0.00
-99.89%
|
0.87
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
0.00
-99.89%
|
0.87
|
| Special Income Charges |
|
—
|
—
|
0.00
-99.89%
|
0.87
|
| Other Special Charges |
|
—
|
—
|
—
|
-0.72
|
| Net Income |
|
-3.46
+28.50%
|
-4.83
+6.13%
|
-5.15
-1.28%
|
-5.09
|
| Pretax Income |
|
-2.91
+42.22%
|
-5.03
+2.95%
|
-5.18
+4.32%
|
-5.42
|
| Net Non Operating Interest Income Expense |
|
—
|
—
|
0.02
+260.00%
|
-0.01
|
| Net Interest Income |
|
—
|
—
|
0.02
+260.00%
|
-0.01
|
| Other Income Expense |
|
0.80
+343.33%
|
-0.33
+46.25%
|
-0.61
-228.18%
|
0.48
|
| Other Non Operating Income Expenses |
|
0.80
+343.33%
|
-0.33
+46.25%
|
-0.61
-55.84%
|
-0.39
|
| Tax Provision |
|
0.55
+380.61%
|
-0.20
-493.94%
|
-0.03
+90.06%
|
-0.33
|
| Tax Rate For Calcs |
|
0.00
+425.00%
|
0.00
+566.67%
|
0.00
-90.32%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.05
|
| Net Income Including Noncontrolling Interests |
|
-3.46
+28.50%
|
-4.83
+6.13%
|
-5.15
-1.28%
|
-5.09
|
| Net Income From Continuing Operation Net Minority Interest |
|
-3.46
+28.50%
|
-4.83
+6.13%
|
-5.15
-1.28%
|
-5.09
|
| Net Income From Continuing And Discontinued Operation |
|
-3.46
+28.50%
|
-4.83
+6.13%
|
-5.15
-1.28%
|
-5.09
|
| Net Income Continuous Operations |
|
-3.46
+28.50%
|
-4.83
+6.13%
|
-5.15
-1.28%
|
-5.09
|
| Net Income Discontinuous Operations |
|
—
|
—
|
—
|
0.00
|
| Normalized Income |
|
-3.46
+28.50%
|
-4.83
+6.13%
|
-5.15
+12.77%
|
-5.90
|
| Net Income Common Stockholders |
|
-3.46
+28.50%
|
-4.83
+6.13%
|
-5.15
-1.28%
|
-5.09
|
| Diluted EPS |
|
-2.79
+73.75%
|
-10.63
+65.03%
|
-30.40
+20.83%
|
-38.40
|
| Basic EPS |
|
-2.79
+73.75%
|
-10.63
+65.03%
|
-30.40
+20.83%
|
-38.40
|
| Basic Average Shares |
|
1.24
+172.75%
|
0.46
+168.12%
|
0.17
+27.93%
|
0.13
|
| Diluted Average Shares |
|
1.24
+172.75%
|
0.46
+168.12%
|
0.17
+27.93%
|
0.13
|
| Diluted NI Availto Com Stockholders |
|
-3.46
+28.50%
|
-4.83
+6.13%
|
-5.15
-1.28%
|
-5.09
|
| Gain On Sale Of PPE |
|
—
|
—
|
0.00
-99.33%
|
0.15
|
| Total Other Finance Cost |
|
—
|
—
|
-0.02
-260.00%
|
0.01
|
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets |
|
13.69
-7.10%
|
14.74
-9.19%
|
16.23
-13.87%
|
18.84
|
| Current Assets |
|
12.65
+0.80%
|
12.55
-9.06%
|
13.80
-16.02%
|
16.43
|
| Cash Cash Equivalents And Short Term Investments |
|
5.37
+71.80%
|
3.13
-18.12%
|
3.82
-48.35%
|
7.40
|
| Cash And Cash Equivalents |
|
5.37
+71.80%
|
3.13
-18.12%
|
3.82
-48.35%
|
7.40
|
| Receivables |
|
3.76
-37.22%
|
5.99
-6.59%
|
6.42
+34.30%
|
4.78
|
| Accounts Receivable |
|
2.23
-22.98%
|
2.90
+12.67%
|
2.57
+6.86%
|
2.41
|
| Gross Accounts Receivable |
|
2.24
-23.42%
|
2.92
+13.02%
|
2.59
+4.02%
|
2.49
|
| Allowance For Doubtful Accounts Receivable |
|
-0.01
+70.37%
|
-0.03
-68.75%
|
-0.02
+80.25%
|
-0.08
|
| Taxes Receivable |
|
1.53
-50.55%
|
3.10
-19.48%
|
3.85
+62.17%
|
2.37
|
| Inventory |
|
2.92
+7.21%
|
2.72
-4.86%
|
2.86
+7.32%
|
2.66
|
| Raw Materials |
|
1.40
-22.59%
|
1.80
+2.15%
|
1.76
+8.49%
|
1.63
|
| Finished Goods |
|
1.82
+49.88%
|
1.21
-8.80%
|
1.33
+28.25%
|
1.04
|
| Prepaid Assets |
|
0.24
-30.59%
|
0.34
-22.37%
|
0.44
-41.99%
|
0.76
|
| Current Deferred Assets |
|
0.21
-19.08%
|
0.26
+9.17%
|
0.24
+10.09%
|
0.22
|
| Other Current Assets |
|
0.15
+40.95%
|
0.10
+320.00%
|
0.03
-95.97%
|
0.62
|
| Total Non Current Assets |
|
1.04
-52.33%
|
2.19
-9.91%
|
2.43
+0.75%
|
2.42
|
| Net PPE |
|
0.31
-52.53%
|
0.65
-28.15%
|
0.91
+3.07%
|
0.88
|
| Gross PPE |
|
2.38
-21.35%
|
3.03
+3.80%
|
2.92
+12.74%
|
2.59
|
| Accumulated Depreciation |
|
-2.08
+12.82%
|
-2.38
-18.17%
|
-2.01
-17.71%
|
-1.71
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.34
-7.14%
|
0.36
+12.35%
|
0.32
+31.17%
|
0.25
|
| Other Properties |
|
1.55
-24.59%
|
2.06
+0.98%
|
2.04
+10.98%
|
1.84
|
| Leases |
|
0.49
-18.84%
|
0.60
+9.21%
|
0.55
+10.14%
|
0.50
|
| Non Current Deferred Assets |
|
0.66
-55.12%
|
1.48
+1.44%
|
1.45
-0.34%
|
1.46
|
| Non Current Deferred Taxes Assets |
|
0.59
-48.56%
|
1.15
+20.65%
|
0.95
+14.48%
|
0.83
|
| Other Non Current Assets |
|
0.07
+12.12%
|
0.07
-9.59%
|
0.07
-5.19%
|
0.08
|
| Total Liabilities Net Minority Interest |
|
9.28
+7.89%
|
8.60
+4.23%
|
8.25
-18.66%
|
10.15
|
| Current Liabilities |
|
4.10
+10.14%
|
3.72
+0.05%
|
3.72
-36.12%
|
5.82
|
| Payables And Accrued Expenses |
|
2.69
+32.77%
|
2.03
-12.07%
|
2.30
-14.67%
|
2.70
|
| Payables |
|
0.95
+57.00%
|
0.61
-27.82%
|
0.84
-48.75%
|
1.64
|
| Accounts Payable |
|
0.95
+57.00%
|
0.61
-27.82%
|
0.84
-48.75%
|
1.64
|
| Current Accrued Expenses |
|
1.74
+22.41%
|
1.42
-3.01%
|
1.46
+38.15%
|
1.06
|
| Current Debt And Capital Lease Obligation |
|
0.28
-46.64%
|
0.52
-24.16%
|
0.69
-35.07%
|
1.06
|
| Current Debt |
|
0.22
-31.89%
|
0.32
-25.06%
|
0.43
-46.66%
|
0.81
|
| Other Current Borrowings |
|
—
|
0.32
-25.06%
|
0.43
-46.66%
|
0.81
|
| Current Capital Lease Obligation |
|
0.06
-70.71%
|
0.20
-22.66%
|
0.26
+2.40%
|
0.25
|
| Current Deferred Liabilities |
|
0.64
+34.10%
|
0.48
+198.75%
|
0.16
-87.47%
|
1.28
|
| Current Deferred Revenue |
|
0.64
+34.10%
|
0.48
+198.75%
|
0.16
-87.47%
|
1.28
|
| Other Current Liabilities |
|
0.49
-29.83%
|
0.69
+22.61%
|
0.57
-27.81%
|
0.78
|
| Total Non Current Liabilities Net Minority Interest |
|
5.19
+6.18%
|
4.88
+7.65%
|
4.54
+4.80%
|
4.33
|
| Long Term Debt And Capital Lease Obligation |
|
0.03
-68.97%
|
0.09
-46.30%
|
0.16
-47.57%
|
0.31
|
| Long Term Capital Lease Obligation |
|
0.03
-68.97%
|
0.09
-46.30%
|
0.16
-47.57%
|
0.31
|
| Tradeand Other Payables Non Current |
|
5.14
+9.17%
|
4.71
+11.22%
|
4.24
+10.34%
|
3.84
|
| Non Current Deferred Liabilities |
|
0.02
-80.46%
|
0.09
-37.86%
|
0.14
-23.08%
|
0.18
|
| Non Current Deferred Revenue |
|
0.02
-80.46%
|
0.09
-37.86%
|
0.14
-23.08%
|
0.18
|
| Stockholders Equity |
|
4.41
-28.12%
|
6.14
-23.07%
|
7.98
-8.28%
|
8.70
|
| Common Stock Equity |
|
4.41
-28.12%
|
6.14
-23.07%
|
7.98
-8.28%
|
8.70
|
| Capital Stock |
|
0.00
|
0.00
-100.00%
|
0.01
+150.00%
|
0.00
|
| Common Stock |
|
0.00
|
0.00
-100.00%
|
0.01
+150.00%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
1.63
+109.42%
|
0.78
+216.35%
|
0.25
+59.10%
|
0.16
|
| Ordinary Shares Number |
|
1.63
+109.42%
|
0.78
+216.35%
|
0.25
+59.10%
|
0.16
|
| Additional Paid In Capital |
|
206.59
+1.67%
|
203.21
+1.15%
|
200.90
+1.79%
|
197.37
|
| Retained Earnings |
|
-197.81
-1.78%
|
-194.35
-2.55%
|
-189.51
-2.79%
|
-184.36
|
| Gains Losses Not Affecting Retained Earnings |
|
-4.38
-60.71%
|
-2.72
+20.33%
|
-3.42
+20.73%
|
-4.31
|
| Total Equity Gross Minority Interest |
|
4.41
-28.12%
|
6.14
-23.07%
|
7.98
-8.28%
|
8.70
|
| Total Capitalization |
|
4.41
-28.12%
|
6.14
-23.07%
|
7.98
-8.28%
|
8.70
|
| Working Capital |
|
8.55
-3.14%
|
8.83
-12.42%
|
10.08
-4.99%
|
10.61
|
| Invested Capital |
|
4.63
-28.31%
|
6.46
-23.17%
|
8.41
-11.54%
|
9.51
|
| Total Debt |
|
0.30
-49.84%
|
0.61
-28.39%
|
0.85
-37.89%
|
1.37
|
| Capital Lease Obligations |
|
0.09
-70.18%
|
0.28
-31.82%
|
0.42
-25.22%
|
0.56
|
| Net Tangible Assets |
|
4.41
-28.12%
|
6.14
-23.07%
|
7.98
-8.28%
|
8.70
|
| Tangible Book Value |
|
4.41
-28.12%
|
6.14
-23.07%
|
7.98
-8.28%
|
8.70
|
| Current Notes Payable |
|
0.22
-31.89%
|
0.32
-25.06%
|
0.43
|
—
|
| Inventories Adjustments Allowances |
|
-0.30
-0.68%
|
-0.30
-25.42%
|
-0.24
|
—
|
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-0.09
+96.33%
|
-2.40
+61.02%
|
-6.15
-44.82%
|
-4.25
|
| Cash Flow From Continuing Operating Activities |
|
-0.09
+96.33%
|
-2.40
+61.02%
|
-6.15
-44.82%
|
-4.25
|
| Net Income From Continuing Operations |
|
-3.46
+28.50%
|
-4.83
+6.13%
|
-5.15
-1.28%
|
-5.09
|
| Depreciation Amortization Depletion |
|
0.14
-21.59%
|
0.18
+40.80%
|
0.12
-32.80%
|
0.19
|
| Depreciation |
|
0.14
-21.59%
|
0.18
+40.80%
|
0.12
-32.80%
|
0.19
|
| Depreciation And Amortization |
|
0.14
-21.59%
|
0.18
+40.80%
|
0.12
-32.80%
|
0.19
|
| Other Non Cash Items |
|
0.17
+8.07%
|
0.16
-6.94%
|
0.17
-22.42%
|
0.22
|
| Stock Based Compensation |
|
0.22
-56.59%
|
0.52
-22.87%
|
0.67
+75.13%
|
0.38
|
| Provisionand Write Offof Assets |
|
—
|
—
|
-0.07
+95.69%
|
-1.53
|
| Deferred Tax |
|
0.36
+427.52%
|
-0.11
-194.59%
|
-0.04
+95.54%
|
-0.83
|
| Deferred Income Tax |
|
0.36
+427.52%
|
-0.11
-194.59%
|
-0.04
+95.54%
|
-0.83
|
| Operating Gains Losses |
|
—
|
—
|
-0.00
+99.86%
|
-0.72
|
| Change In Working Capital |
|
2.48
+46.25%
|
1.69
+187.72%
|
-1.93
-161.64%
|
3.13
|
| Change In Receivables |
|
0.43
+288.70%
|
-0.23
-5650.00%
|
-0.00
-100.20%
|
1.97
|
| Changes In Account Receivables |
|
0.43
+288.70%
|
-0.23
-5650.00%
|
-0.00
-100.20%
|
1.97
|
| Change In Inventory |
|
-0.39
-310.87%
|
0.18
|
0.00
+100.00%
|
-0.10
|
| Change In Prepaid Assets |
|
1.09
-1.90%
|
1.11
+461.76%
|
-0.31
+33.48%
|
-0.46
|
| Change In Payables And Accrued Expense |
|
1.14
+429.17%
|
0.22
+163.34%
|
-0.34
-138.66%
|
0.88
|
| Change In Accrued Expense |
|
0.29
+1452.63%
|
0.02
-85.04%
|
0.13
-81.30%
|
0.68
|
| Change In Payable |
|
0.85
+330.46%
|
0.20
+142.09%
|
-0.47
-330.54%
|
0.20
|
| Change In Account Payable |
|
0.42
+249.64%
|
-0.28
+67.82%
|
-0.86
-450.32%
|
-0.16
|
| Change In Other Working Capital |
|
0.38
-35.01%
|
0.58
+152.17%
|
-1.11
-204.34%
|
1.06
|
| Change In Other Current Liabilities |
|
-0.17
-8.07%
|
-0.16
+6.94%
|
-0.17
+22.07%
|
-0.22
|
| Investing Cash Flow |
|
-0.08
-3900.00%
|
-0.00
+99.22%
|
-0.26
-160.61%
|
-0.10
|
| Cash Flow From Continuing Investing Activities |
|
-0.08
-3900.00%
|
-0.00
+99.22%
|
-0.26
-160.61%
|
-0.10
|
| Net PPE Purchase And Sale |
|
-0.08
-3900.00%
|
-0.00
+99.26%
|
-0.27
-96.35%
|
-0.14
|
| Purchase Of PPE |
|
-0.08
-3900.00%
|
-0.00
+99.26%
|
-0.27
-96.35%
|
-0.14
|
| Capital Expenditure |
|
-0.08
-3900.00%
|
-0.00
+99.26%
|
-0.27
-96.35%
|
-0.14
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Net Other Investing Changes |
|
—
|
0.01
+36.36%
|
0.01
-71.05%
|
0.04
|
| Financing Cash Flow |
|
3.03
+80.79%
|
1.68
-32.66%
|
2.49
-66.35%
|
7.40
|
| Cash Flow From Continuing Financing Activities |
|
3.03
+80.79%
|
1.68
-32.66%
|
2.49
-66.35%
|
7.40
|
| Net Issuance Payments Of Debt |
|
-0.40
+16.01%
|
-0.48
+46.20%
|
-0.89
-139.04%
|
-0.37
|
| Issuance Of Debt |
|
—
|
—
|
0.52
+318.70%
|
0.12
|
| Repayment Of Debt |
|
-0.40
+16.01%
|
-0.48
+46.20%
|
-0.89
-79.88%
|
-0.50
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
0.00
+100.00%
|
-0.12
+74.30%
|
-0.47
|
| Net Long Term Debt Issuance |
|
—
|
0.00
+100.00%
|
-0.12
+74.30%
|
-0.47
|
| Short Term Debt Issuance |
|
—
|
—
|
0.52
+318.70%
|
0.12
|
| Short Term Debt Payments |
|
-0.40
+16.01%
|
-0.48
+37.86%
|
-0.77
-55.73%
|
-0.50
|
| Net Short Term Debt Issuance |
|
-0.40
+16.01%
|
-0.48
+37.86%
|
-0.77
-106.95%
|
-0.37
|
| Net Common Stock Issuance |
|
3.08
+72.53%
|
1.78
-37.80%
|
2.87
-62.03%
|
7.55
|
| Common Stock Payments |
|
-0.00
|
0.00
|
—
|
—
|
| Repurchase Of Capital Stock |
|
-0.00
|
0.00
|
—
|
—
|
| Proceeds From Stock Option Exercised |
|
0.08
|
0.00
|
0.00
-100.00%
|
0.22
|
| Net Other Financing Charges |
|
0.27
-26.54%
|
0.37
-27.57%
|
0.52
|
—
|
| Changes In Cash |
|
2.86
+495.30%
|
-0.72
+81.54%
|
-3.92
-228.60%
|
3.05
|
| Effect Of Exchange Rate Changes |
|
-0.62
-2025.00%
|
0.03
-90.72%
|
0.34
+171.65%
|
0.13
|
| Beginning Cash Position |
|
3.13
-18.12%
|
3.82
-48.35%
|
7.40
+75.26%
|
4.22
|
| End Cash Position |
|
5.37
+71.80%
|
3.13
-18.12%
|
3.82
-48.35%
|
7.40
|
| Free Cash Flow |
|
-0.17
+93.00%
|
-2.40
+62.62%
|
-6.42
-46.43%
|
-4.38
|
| Interest Paid Supplemental Data |
|
0.01
-50.00%
|
0.02
+29.41%
|
0.02
-29.17%
|
0.02
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
0.00
-100.00%
|
0.77
|
| Change In Income Tax Payable |
|
0.43
-9.05%
|
0.47
+19.95%
|
0.40
+10.00%
|
0.36
|
| Change In Tax Payable |
|
0.43
-9.05%
|
0.47
+19.95%
|
0.40
+10.00%
|
0.36
|
| Common Stock Issuance |
|
3.08
+72.59%
|
1.78
-37.80%
|
2.87
-62.03%
|
7.55
|
| Issuance Of Capital Stock |
|
3.08
+72.59%
|
1.78
-37.80%
|
2.87
-62.03%
|
7.55
|
| Sale Of Intangibles |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-02-10 View
- 8-K2026-01-28 View
- 8-K2026-01-12 View
- 42026-01-02 View
- 42026-01-02 View
- 42026-01-02 View
- 42026-01-02 View
- 42026-01-02 View
- 42026-01-02 View
- 8-K2026-01-02 View
- 10-Q2025-11-04 View
- 8-K2025-10-23 View
- 8-K2025-10-09 View
- 8-K2025-09-29 View
- 8-K2025-09-26 View
- 8-K2025-08-29 View
- 10-Q2025-08-07 View
- 42025-06-20 View
- 42025-06-20 View
- 42025-06-20 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|